World

Roundup: U.S. crude supplies up, other petroleum data mixed

Dec 01, 2022

Houston (US), December 1: U.S. crude oil refinery inputs averaged 16.6 million barrels per day (b/d) during the week ending Nov. 25, 228,000 b/d more than the previous week's average, according to a weekly report issued by the U.S. Energy Information Administration on Wednesday.
Refineries operated at 95.2 percent of their operable capacity last week, compared with 93.9 percent in the previous week, said the Weekly Petroleum Data report.
During the same period, both gasoline and distillate fuel production grew, averaging 9.4 million b/d and 5.3 million b/d respectively.
U.S. commercial crude oil inventories, excluding those in the Strategic Petroleum Reserve, declined by 12.6 million barrels from the previous week to 419.1 million barrels, about 8 percent below the five-year average for this time of year.
Total motor gasoline inventories surged by 2.8 million barrels from last week, about 4 percent below the five-year average for this time of year.
Last week, both finished gasoline and blending components inventories went up. Distillate fuel inventories rose by 3.5 million barrels during the same period, about 11 percent below the five-year average for this time of year.
Propane/propylene inventories grew by 1.6 million barrels from last week, 13 percent above the five-year average for this time of year.
Total commercial petroleum inventories fell by 8.8 million barrels last week.
Total products supplied over the last four-week period averaged 20.5 million b/d, down by 1.1 percent from the same period last year.
Over the past four weeks, motor gasoline product supplied averaged 8.6 million b/d, down by 6.1 percent from the same period last year.
Distillate fuel product supplied averaged 3.9 million b/d over the past four weeks, down by 9.9 percent from the same period last year.
Jet fuel product supplied was up 3.7 percent compared with the same four-week period last year.
Source: Xinhua

More news

Piramal Pharma's FY2026 Annual Report showcases global scale, innovation-led growth and sustainability milestones

Mumbai (Maharashtra) [India], July 7: Piramal Pharma Limited (PPL) (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, health and wellness company, released its Annual Report for FY2026, highlighting a year of strengthening its global platform, investing in differentiated capabilities, advancing sustainability, and delivering quality across operations. The report reflects Piramal Pharma's continued commitment to improving patient outcomes through science-led innovation, operational excellence and quality, while building a resilient global platform that serves customers across regulated markets worldwide.

Jul 07, 2026